The phase 3 ADAURA study (NCT02511106) assessed completely resected early-stage (stage II to IIIA) NSCLC patients with EGFR mutation-positive and reported that DFS was significantly longer in the osimertinib group than placebo group (not reached vs. 19.6 months; HR=0.17, 99.06% CI: 0.11-0.26, p<0.001) (38). Here, EGFR is linked to non-small cell lung carcinoma.